v3.26.3
Equity Method Investments (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Apr. 30, 2024
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2026
Sep. 30, 2025
Dec. 31, 2025
Aug. 31, 2024
Schedule Of Equity Method Investments [Line Items]              
Loss from equity method investment   $ 7,312 $ 15,834 $ 32,030 $ 51,579    
Equity method investments   47,783   47,783   $ 79,972 [1]  
Prepaid expenses and other current assets   70,944   70,944   44,070 [1]  
Research and development   143,506 112,874 419,590 335,536    
Other current liabilities [2]   212,114   212,114   120,222 [1]  
Gondola Bio, LLC | Transition Service Agreement And Sublease Agreement              
Schedule Of Equity Method Investments [Line Items]              
Operating expenses   600 1,400 3,100 4,100    
Prepaid expenses and other current assets   1,000   1,000   4,500  
Other current liabilities   1,000   1,000   1,500  
Gondola Bio, LLC | Transition Service Aggrement              
Schedule Of Equity Method Investments [Line Items]              
Research and development   $ 400 0 $ 800 1,200    
Gondola Bio, LLC              
Schedule Of Equity Method Investments [Line Items]              
Equity ownership percentage approximately   13.10%   13.10%     45.50%
Loss from equity method investment   $ 0 7,100 $ 6,400 23,000    
Equity method investments   0   0   6,400  
Gondola Bio, LLC | Transition Service Agreement And Sublease Agreement              
Schedule Of Equity Method Investments [Line Items]              
Other income   $ 1,800 3,200 $ 6,500 8,600    
BridgeBio Oncology Therapeutics, Inc.              
Schedule Of Equity Method Investments [Line Items]              
Equity ownership percentage approximately   18.20%   18.20%      
Loss from equity method investment   $ 7,100 $ 8,700 $ 25,000 $ 28,600    
Equity method investments   47,500   47,500   72,500  
Payment for private equity financing with external investors $ 200,000            
Percentage of ownership reduced for private equity financing 37.90%            
BridgeBio Oncology Therapeutics, Inc. | Level 1              
Schedule Of Equity Method Investments [Line Items]              
Investors contribution fair value   $ 59,800   $ 59,800   $ 182,700  
[1] The condensed consolidated balance sheet as of December 31, 2025 is derived from the audited consolidated financial statements as of that date.
[2] Including related party amounts of nil and $2,003 as of September 30, 2026 and December 31, 2025, respectively (as described in Note 9).